Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Beam Therapeutics (BEAM) Return on Sales (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Return on Sales for 7 consecutive years, with 0.06% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 295.0% to 0.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 2.37%, a 346.0% increase, with the full-year FY2025 number at 0.57%, up 536.0% from a year prior.
  • Return on Sales was 0.06% for Q4 2025 at Beam Therapeutics, up from 11.62% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.45% in Q4 2023 to a low of 33399.0% in Q1 2021.
  • A 5-year average of 2168.96% and a median of 6.18% in 2023 define the central range for Return on Sales.
  • Peak YoY movement for Return on Sales: tumbled -2877267bps in 2021, then skyrocketed 3339004bps in 2022.
  • Beam Therapeutics' Return on Sales stood at 1.24% in 2021, then tumbled by -231bps to 4.11% in 2022, then skyrocketed by 111bps to 0.45% in 2023, then plummeted by -762bps to 3.01% in 2024, then surged by 98bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Return on Sales are 0.06% (Q4 2025), 11.62% (Q3 2025), and 12.08% (Q2 2025).